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In the European Union, labels (Summaries of Product Characteristics, SmPCs) of biosimilars and their
reference products are in many instances almost identical (following a generic approach) despite
different data requirements for the authorization of biosimilars and generics. To understand physicians'
preferences on type and detail of information in the biosimilar label and their use of information sources
when prescribing biologics including biosimilars, EuropaBio surveyed 210 physicians across seven Eu-
ropean countries. Among surveyed physicians, 90.5% use the label frequently or occasionally as an in-
formation source and 87.2% deemed a clear statement on the origin of data helpful or very helpful. When
comparing excerpts from the label of an authorized biosimilar and modiﬁed texts with additional in-
formation, 78.1e82.9% preferred the samples with additional information. This survey shows that the
label is an appropriate vehicle for providing physicians with information about biologics and that phy-
sicians prefer more product-speciﬁc information in the biosimilar label.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Biosimilars are biological medicinal products (biologics) that are
similar to a reference medicinal product (reference product) which
has already been authorized for human use on the basis of a full
dossier. Biosimilars may offer a less costly alternative to existing
biologics that have lost their exclusivity rights and thereby have the
potential to broaden patient access to biological medicines (EU
Commission, 2013).
Biologics (including biosimilars) are produced by living systems
(such as cells), often large in molecular size and challenging to
characterize. Consequently, a degree of inherent variability in
addition to batch-to-batch variability exists and identical versions
cannot be produced (Schneider et al., 2012; Weise et al., 2011).
Furthermore, these products may have multiple mechanisms oficines; CHMP, Committee for
edicines Agency; EPAR, Eu-
Biosimilars Initiative; NMPR,
t; SmPC, Summary of Product
cientiﬁc Communication Ltd,
allersten).
r Inc. This is an open access articleactionwith some of them not being fully understood. Therefore, the
similarity of biosimilars to their reference product in terms of
structure, function, biological activity, quality, safety and efﬁcacy
needs to be established through a comprehensive comparability
exercise that generally includes clinical studies comparing the
biosimilar with a reference product (CHMP, 2014). This is a sub-
stantial difference compared to the clinical requirements for
approval of generics for small molecule drugs where only bio-
equivalence clinical studies are required (EP and the Council of the
EU, 2015).
In the European Union (EU), biologics, including biosimilars, are
assessed by the European Medicines Agency (EMA) through the
Centralized Procedure, not at the national level (CHMP, 2014). Since
2006, 22 biosimilar products relating to 6 drug substances have
been authorized in the EU (EMA, 2015; GaBI, 2016). Recently, the
label (Summary of Product Characteristics, SmPC) of a biosimilar
tended to become identical to that of its respective reference
product. Accordingly, data in the label were generated with the
reference product (without indicating this fact), whereas data
generated with the biosimilar product (according to the re-
quirements for approval) were not included in the label. The main
difference in the biosimilar label compared with the reference
product label is a brief statement that the product is a biosimilar
(EU Commission, 2009; EMA, 2012).under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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frequently as synonym for the USPI (US Package Insert) or the SmPC
in the US and Europe, respectively. However, depending on the
context, the term “label” can refer to all product information doc-
uments (e.g. the package leaﬂet). In this article, “label” refers to the
SmPC, which has been the subject of the survey presented here.
In 2012, the article “Setting the stage for biosimilar monoclonal
antibodies” by Schneider et al. (2012) highlighted three scenarios
for the content of the biosimilar label. These ranged from having
identical labels for biosimilars and reference products to having a
biosimilar label that only includes information generated (or
conﬁrmed) with the biosimilar. The third scenario suggested a
“hybrid” label, containing information from the reference and the
biosimilar product. Furthermore, the authors illustrated the po-
tential of the label as a powerful instrument to provide summarized
information regarding evidence that was generated with a partic-
ular medicinal product. To date, it is not known to which extent
physicians use the label as an information source when prescribing
biologics (including biosimilars). It is also not known whether
physicians (or other stakeholders) consider the information in the
current biosimilar labels sufﬁcient or perceive a need for additional
information, and, if so, what type of additional information should
be included in a “hybrid” label.
Therefore, EuropaBio, the European Association for Bio-
industries, with funding from six companies (AbbVie, Amgen, MSD,
Novartis, Novo Nordisk and Pﬁzer) commissioned a survey among
physicians in the EU to understand which information sources they
currently use when prescribing and monitoring the use of biologics
including biosimilars, and which information they deem most
helpful to be included in the biosimilar label.
2. Methods
2.1. Survey design and participants
The survey was designed and piloted between November and
March 2015, and carried out as an anonymized online question-
naire among physicians in seven EU countries (France, Germany,
Italy, Poland, Spain, Sweden and the United Kingdom [UK]) during
April 2015 in compliance with applicable national guidelines and
regulation. No Ethics Committee approval was required for the
conduct of the study. Survey participants were members of panels
of physicians (approximately 250e800 physicians per country)
who agreed earlier to participate in such survey studies. Eligible
physicians had to be specialized in dermatology, endocrinology,
gastroenterology, hematology, nephrology, oncology or rheuma-
tology and had to have at least three years of practice experience.
The survey was designed to only allow the submission of a fully
completed survey, which was remunerated with 50 Euro inde-
pendent of the selected answer options. Tomaintain geography and
specialty balanced, the ﬁrst 4 (dermatology, endocrinology,
gastroenterology, hematology and oncology) or 5 (nephrology and
rheumatology) completed responses per country and specialty
collected were included in the analysis.
The survey was split into two parts that explored the physicians'
current knowledge and use of biologics and available information
sources about these products (Part 1) and the physicians' prefer-
ences for the information they would like to see in the ofﬁcial
product information (label, Summary of Product Characteristics
SmPC) of a biosimilar (Part 2). Physicians had to complete Part 1 of
the survey before proceeding to Part 2. In Part 2, participants had
access to background information on the format and content of
authorized documents which provide information on medicinal
products (label, package leaﬂet, and the European Public Assess-
ment Report). Part 2 of the survey also included sample texts forthree different sections of the label: “Pharmacodynamic proper-
ties” (Section 5.1 according to the EU SmPC template; Sample 1),
“Posology and method of administration” (Section 4.2; Sample 2),
and “Undesirable effects” (Section 4.8; Sample 3) (see Table S1 for
structure of the EU SmPC with section numbers and titles). Each
sample text was provided in two different versions: option A and B.
Option A always comprised text samples identical to the current
biosimilar label. Option B comprised text samples that included
additional information and referred to the respective products used
for generation of the included data. Screen shots of survey ques-
tions and answer options as well as all sample texts are available as
online supplementary material.
The survey was piloted by ﬁve English-speaking physicians in
order to ensure that the questions were understood and that the
survey could be completed within the proposed time frame
(25 min). Since some respondents had difﬁculties in identifying the
differences between the current and modiﬁed label samples (i.e.
options A and B), a feature was added to display the current and the
modiﬁed label sample simultaneously, and color markings were
added to highlight the differences between the two versions. The
ﬁnal English version of the survey was translated and displayed in
local language to the participating physicians.
2.2. Biosimilar label sample texts
The texts in the label samples in Part 2 of the survey were based
on the SmPC and the European Public Assessment Report (EPAR) for
epoetin alfa Binocrit® (Sandoz Pharmaceuticals), a biosimilar of the
reference product Eprex® (Janssen-Cilag). Physicians were
informed that although this speciﬁc biosimilar medicinal product
was used in the examples, the survey aimed to assess their general
preferences for how biosimilar product information should be
displayed in the label, regardless of therapeutic area or product
class.
The sample texts like all other survey questions and answer
options were selected and prepared by a multi-disciplinary team of
specialists in regulatory affairs, public policy and scientiﬁc
communication, and reviewed by a panel of medical doctors with
backgrounds in clinical science, drug safety and as former
regulators.
2.3. Outcomes and analysis
The objective of the survey was to explore physicians' prefer-
ences for the content of the EU biosimilar label. In order to verify
the relevance of the label for their routine practice, physicians were
also asked which information sources they use to assist them in
prescribing and administering biologics (including biosimilars).
The survey responses to individual questions and options were
summarized as numbers and percentages of responding physicians.
The number of 30 evaluable questionnaires per country was
considered the minimum number to ensure a representative
sample size.
3. Results
3.1. Survey part 1: characterization of participants and their use of
information sources
3.1.1. Geographical spread and experience of participating
physicians
Responses from 210 physicians in seven EU countries (France,
Germany, Italy, Poland, Spain, Sweden and the UK) were analyzed.
In each country, 30 eligible physicians were enrolled including
nephrologists and rheumatologists (n¼ 5 for each specialty) as well
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ogists and oncologists (n ¼ 4 for each specialty). The vast majority
of physicians (83.9%) hadmore than 10 years of practice experience,
and 88.6% stated they were aware of the regulatory deﬁnition of a
biosimilar before they read about it in the introduction part of the
survey. Almost all physicians (89.5%) had already prescribed a
biologic, and 59.0% had already prescribed a biosimilar. Since in-
formation in the label samples displayed in Part 2 of the survey was
taken from the biosimilar Binocrit® (Sandoz Pharmaceuticals) and
its reference product Eprex® (Janssen-Cilag), physicians were also
asked about their experience with these speciﬁc products. The
biosimilar and its reference product had been previously prescribed
by 29.5% and 43.3% of physicians, respectively.3.1.2. Use of the label (SmPC)
The label was among the three most often referenced sources of
information that the surveyed physicians use when prescribing a
biological product including a biosimilar (Fig. 1a). The combined
percentage scores for physicians who reported using a particular
source “frequently” or “occasionally” were 92.4% for peer-reviewed
journals, 91.5% for professional guidelines and 90.5% for the label.
Among frequent or occasional users of a particular source, the label
was the most frequently consulted source of information when
physicians prescribed a biologic for the ﬁrst time (Fig. 1b), and the
second most important source to answer questions from patients
(in this speciﬁc situation, the physicians deemed the package leaﬂet
as the most important source).Fig. 1. a: Physicians' use of information sources. Survey question: “How familiar are you with
and/or biosimilar products, including following-up the patient during treatment?”. Bars show th
physicians). b: Use of information sources in medical practice. Survey question: “When do y
percentage of physicians responding “yes” to the use of the respective source in each situatio
to be familiar with the source and using it frequently or occasionally).3.1.3. Relative importance of label sections
When asked about the importance of the mandatory sections of
the SmPC based on section numbers and headings according to the
EU SmPC template (EU Commission, 2009) almost all surveyed
physicians (91.9%) considered Section 4, “Clinical particulars” as the
most important, followed by Section 5 “Pharmacological proper-
ties” (73.8%) (see Table S1 for structure of the EU SmPCwith section
numbers and titles). When asked about the most relevant sub-
sections, these physicians selected “Contraindications”, “Thera-
peutic indications” and “Posology and method of administration”
within Section 4 and “Preclinical safety data”, “Pharmacokinetic
properties” and “Pharmacodynamic properties” within Section 5
(Fig. 2). Notably, of the three subsections of Section 5, “Pharmaco-
dynamic Properties”, where clinical data and the biosimilar state-
ment are found in the SmPC, received the lowest importance rating.3.2. Survey part 2: physician preferences for speciﬁc information in
the biosimilar label
In Part 2 of the survey, physicians were ﬁrst asked to score the
helpfulness of potential additional information in the biosimilar
label. Thereafter, physicians were asked for their preferences be-
tween samples of Section 5.1 “Pharmacodynamic properties”, 4.2
“Posology and method of administration”, and 4.8 “Undesirable
effects” from the label of an authorized biosimilar and modiﬁed
sample texts with additional information (see methods for more
detail). Assessment of the current or future legal validity of theeach of the following sources for the purpose of prescribing and administering originator
e percentage of physicians giving the respective answers for each source (basis N ¼ 210
ou consult the sources listed below?” *Multiple selections were possible. Bars show the
n (basis for the calculation of percentages was the number of physicians who reported
Fig. 2. Most important sub-sections of the label (SmPC). Survey questions: “Which of these [title of main section] is/are most important?” *Multiple selections were possible. Bars show
the percentage of physicians who rated the respective sub-section as important (basis for the calculation of percentages was the number of physicians who considered the
respective main section among the three most important sections of the label; n ¼ 193 for Section 4 “Clinical particulars”; n ¼ 155 for Section 5 “Pharmacological properties”).
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sample texts was not within the scope of the survey.
3.2.1. Helpfulness ratings for potential additional information in the
biosimilar label
A clear statement on the origin of clinical data, i.e. which data
were generated by the reference product and which by the bio-
similar, received the highest rating for helpfulness (scored as either
“very helpful” or “helpful” by 87.2% of physicians), followed by the
distinction of adverse events by class and individual product
(85.8%) (Fig. 3). Inclusion of results from comparative clinical trials
conducted for approval of the biosimilar, information about the
origin of non-clinical data and highlighting which clinical in-
dications were extrapolated were considered “very helpful” or
“helpful” by 70e80% of physicians. Only a small proportion of
physicians (2.9%) deemed the potential additional contents “not
helpful”.
3.2.2. Preferences and helpfulness ratings for modiﬁed label
samples
Most physicians (78.1e82.9%) preferred the modiﬁed label
samples with additional information about what data had been
generated with which product (Fig. 4, full illustration of the sample
texts available as supplementary material). The clariﬁcation of
clinical data origin and addition of comparability study dataFig. 3. Helpfulness ratings of potential additional contents of the biosimilar label (SmPC)
administering a biosimilar product, including following-up the patient during treatment, that the
giving the respective helpfulness scores for each of the potential additional contents.(Section 5.1), the clariﬁcation of pediatric clinical data origin
(Section 4.2, dosing recommendation), and a statement that not all
adverse events may have been observed with all products (Section
4.8) were deemed “very helpful” or “helpful” by 77.1%, 67.6% and
65.3% of physicians, respectively.
A modiﬁed biosimilar statement (Section 5.1), indicating that
the similarity has been evaluated in preclinical and clinical studies
and explicitly stating the name of the reference product was
considered “helpful” or “very helpful” by 70.9% of physicians. The
current mandatory biosimilar statement, indicating that the prod-
uct is a biosimilar and that detailed information is available on the
EMA homepage, was considered “helpful” or “very helpful” by
60.4% of physicians.
Since in practice only certain selected sections or even only one
section may be read by a physician, the modiﬁed biosimilar state-
ment was included and tested for helpfulness rating in all three
label samples. All three helpfulness ratings of that statement that
have been collected independently by this means showed consis-
tently high scores of 70.9%, 68.6% and 71.9%, respectively.3.3. Subgroup analyses
3.3.1. Use of information sources and preferences of label samples
by country
The proportion of physicians who use particular information. Survey questions: “How helpful would it be for you, for the purpose of prescribing and
SmPC states [potential additional information]?”. Bars show the percentage of physicians
Fig. 4. Preferences for modiﬁed sample texts of the biosimilar label (SmPC). Survey questions: “Please indicate which SmPC option would be most helpful for you for the purpose of
prescribing and administering a biosimilar product, including following-up the patient during treatment”. Bars show the percentage of physicians preferring either the current or the
modiﬁed sample text of the label sub-sections when displayed side-by side. The current and modiﬁed SmPC sample texts used in the survey are available as supplemental material.
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similar (i.e. 10% difference compared to overall results) across six
of the seven EU countries that were included in the survey (Table S2
in supplementary materials). In Sweden, the proportion of physi-
cians who were frequent and occasional users of all prompted in-
formation sources except national or international guidelines was
13.8e26.2% lower than the average; for the guidelines it was 4.7%
less.
In all seven countries and for all three samples on Sections 5.1,
4.2 and 4.8, respectively, the majority of surveyed physicians
(60.0e93.3%) preferred the modiﬁed label sample versions with
additional information over the current label samples (Table 1). The
highest preferences for the modiﬁed label samples were recorded
in Germany and Poland while the lowest (but still favorable) rates
were recorded in France.
Preferences and helpfulness ratings stratiﬁed by prescribing
experience and the situation when the label is used as an infor-
mation source.
The preference for the modiﬁed label samples was higher
among physicians without experience in prescribing biosimilars
than among physicians who have already prescribed biosimilars
(Table 2). Prior experience or lack of experience in prescribing an
epoetin alfa product (Eprex or any of its biosimilars) did not sub-
stantially inﬂuence the preference for the modiﬁed version of any
of the label samples.
Among physicians using the label as an information source prior
to ﬁrst-time prescriptions, preference rates for the modiﬁed label
samples were higher than among the other physicians (Table 2).Table 1
Preferences for the modiﬁed label (SmPC) samples e per country.
All countries (n ¼ 210) France
(n ¼ 30)
Section 5.1
“Pharmacological properties”
82.9% 60.0%
Section 4.2
“Posology and method of administration”
78.1% 60.0%
Section 4.8
“Undesirable effects”
80.0% 60.0%
Fields with >10% difference compared to overall results highlighted in grey.4. Discussion and conclusion
The results of this survey among 210 physicians in seven EU
countries, representing seven specialties, demonstrate that the la-
bel is a key information source and the majority of these physicians
prefer a biosimilar label (SmPC) which includes more information
on the speciﬁc product. The label for biologics including biosimilars
is used as a main source of information, almost as frequently as
professional guidelines and peer-reviewed publications; thus,
reinforcing the expectation (EU Commission, 2009) that the label is
the appropriate vehicle for information and guidance. The different
pattern in use of information sources in Sweden may be related to
the common use of a public web portal that provides a wide range
of product-related information (NMPR, 2008). Additional infor-
mation in the biosimilar label, speciﬁcally (a) clarifying which
product (the biosimilar or the reference product) generated which
clinical data, (b) inclusion of additional statements indicating that
the product is a biosimilar, and (c) that similarity has been evalu-
ated in preclinical and clinical studies, were preferred and consid-
ered helpful or very helpful according to this survey.
This report is the ﬁrst fully published, comprehensive investi-
gation on EU physicians' use of different information sources
including the label and preferences for the content of the biosimilar
label. The predominant use of the label, particularly among those
who use it for ﬁrst-time prescriptions, underlines the need for
multi-stakeholder discussions on which information should be
included in a biosimilar label.
The frequent use of the label identiﬁed in this survey is in line
with the results of a previous survey that focused on the familiarityGermany
(n ¼ 30)
Italy
(n ¼ 30)
Poland
(n ¼ 30)
Spain
(n ¼ 30)
Sweden
(n ¼ 30)
UK
(n ¼ 30)
93.3% 80.0% 93.3% 86.7% 86.7% 80.0%
93.3% 76.7% 83.3% 90.0% 70.0% 73.3%
90.0% 83.3% 76.7% 83.3% 83.3% 83.3%
Table 2
Preferences for the modiﬁed label (SmPC) samples e per prescribing experience and use of the label as information source for ﬁrst-time prescriptions.
Prior biosimilar prescription
experience
Prior epoetin prescription
experience
Use of SmPC for ﬁrst-time
prescriptionsa
Yes (n ¼ 124) No (n ¼ 86) Yes (n ¼ 106) No (n ¼ 104) Yes (n ¼ 128) No (n ¼ 62)
Section 5.1
“Pharmacological properties”
77.4% 90.7% 80.2% 85.6% 86.7% 75.8%
Section 4.2
“Posology and method of administration”
75.0% 82.6% 77.4% 78.8% 84.4% 69.4%
Section 4.8
“Undesirable effects”
78.2% 82.6% 78.3% 81.7% 81.3% 72.6%
None of the subgroup results differs >10% from the overall results.
a Among physicians who indicated “frequent” or “occasional” use of the SmPC (n ¼ 190).
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biosimilar naming and substitution (ASBM, 2015; Dolinar and
Reilly, 2014). Among physicians who participated in that survey,
86% used the label/SmPC “always” or “occasionally” (compared
with 90.5% reported here). However, that survey did not distinguish
between the “label” and the SmPC (which could also be understood
as the package leaﬂet by European prescribers) and also did not
verify whether results are consistent across countries or speciﬁc
participant subgroups.
The survey reported here showed consistency of results in favor
of the modiﬁed versions of the label when physicians were shown
three real text samples and modiﬁcations thereof. This outcome
was independent of the physicians' specialty and geographic loca-
tion. Notably, the modiﬁed sample texts comprised different de-
grees of speciﬁcity with respect to the additional information.
Samples on Sections 5.1 and 4.2 provided rather speciﬁc clariﬁca-
tion of which clinical data had been generated by the biosimilar or
the reference product, whereas the sample on Section 4.8 included
a disclaimer-like statement that not all listed adverse events may
have been observedwith all products. The ratings for helpfulness of
the additional information in the modiﬁed label samples tended to
match their speciﬁcity.
Notably, the preference for themodiﬁed label samples wasmore
prevalent among physicians who used the label when prescribing a
medicine for the ﬁrst-time and physicians who did not have pre-
vious experience in prescribing biosimilars.
Shortly before the completion of this survey, a similar study by
the Alliance for Safe Biologic Medicines (ASBM) among 400 phy-
sicians located in the US has been presented (ASBM, 2013). In line
with the ﬁndings among physicians in the EU as presented here, US
physicians also considered clariﬁcations and additions to the bio-
similar label very important, with the highest preference for text
indicating that the drug is a biosimilar. Notably, the US ﬁndings are
based on views of physicians who most likely did not yet have any
experience in prescribing biosimilars since no biosimilar was
authorized in the US before March 2015 (when Zarxio®, Sandoz,
was authorized as ﬁrst biosimilar in the US) (FDA, 2015). On the
contrary, physicians in the EU have considerably more practical
experience with the biosimilar label, due to the fact that for several
years, the EU has been the ﬁrst and only jurisdiction in the world to
adopt a regulatory framework for the authorization of biosimilars.
The physicians' ranking of label sections by importance in Part 1
of the survey matched the selection of label sections that have been
used for the preparation of sample texts. “Posology and method of
administration” and “Undesirable effects” (used for two of the three
samples) are both sub-sections in Section 4 (“Clinical particulars”)
which was rated as the most important main section.
“Pharmacodynamic properties”, the current location of clinical
data (EU Commission, 2009) and used for the third sample text, was
ranked lower in importance. The lower rating in importance of thissub-section may suggest that it is not clear for physicians that it
contains important clinical data. As a consequence of this “un-
awareness” about the location of clinical data, current clinical in-
formation as well as potential additional information in the future
may go unnoticed by physicians consulting the label. The same
might be true for the biosimilar statement that is also located in this
sub-section.
For robustness of the results, physicians in specialties which
traditionally have the most frequent use of biologics were enrolled
in this survey, even though biosimilars are not available in all of
these therapeutic areas. To minimize unintended bias, samples
were based on EMA-authorized labels and publicly available in-
formation. In order to avoid any language bias, the survey was
displayed to the physicians in local language.
Recruitment of physicians who had at least three years' practice
experience and agreed to participate in such survey studies
comprise a selection for ‘more interested’ or ‘more advanced’
physicians. Indeed, the 89.5% participating physicians who had
already prescribed a biologic (originator and/or biosimilar) may not
correspond with the average physicians in the selected specialties.
However, this selection was intentional to allow for survey re-
sponses to be substantiated by the physician's own experience. The
study lacks a control question such as if and how the physician's
decisions (e.g. on choice of treatment or approach to physician-
patient communication) would have been inﬂuenced in case they
would have been aware about the additional information. To cor-
rect for a general preference in favor of additional information, we
present and discuss the results mainly in comparison with each
other rather than the perceived helpfulness rankings of the indi-
vidual options.
Since the time for completion of the survey had to be restricted
to a reasonable duration (approx. 25 min), the label samples were
limited to one medicinal product. For the same reason, samples
were only prepared for two biosimilar label options (current label,
being a copy of the reference product's label, and a modiﬁed
version, containing a combination of reference and biosimilar data).
Inclusion of additional samples based only on biosimilar data
(representing the third option suggested by Schneider et al. (2012))
would have exceeded the reasonable duration of the survey and
required access to data that are not publicly available. Due to the
limited time available to complete the survey, there were also no
additional questions to validate the categories for frequency of
usage of information sources, or for rating the helpfulness of a
source. For presenting the results, qualitatively similar categories
such as “frequently” and “occasionally” or “very helpful” and
“helpful” have been combined.
It remains to be seen whether the physicians' preferences as
identiﬁed in this survey could be implemented under current
guidelines or whether an update would be ﬁrst required. Currently,
the content of a biosimilar label in the EU is outlined in the general
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uments (EMA, 2012) which in turn is based on the Guideline on
Summary of Product Characteristics published by the European
Commission (EU Commission, 2009). Format changes to the bio-
similar label in comparison to the reference product label are only
acceptable as long as the content remains consistent and any
additional information in the biosimilar label is supported and
justiﬁed. Decisions on the inclusion of biosimilar-speciﬁc infor-
mation may depend on the perception whether the prescription/
use of biological medicines may require more information, and that
appropriate prescribing/use of biosimilars could be improved by
providing physicians with additional information. Since better in-
formation and transparency about the origin of data are considered
a main driver of conﬁdence in biosimilars and their adoption in
medical practice, the biotech industry as represented by EuropaBio
and its members generally supports steps in this direction (Watson
et al., 2015).
In conclusion, the results of the survey presented here indicate
that the label (SmPC), along with professional guidelines and peer-
reviewed publications, is the most frequently used source of in-
formation and therefore an appropriate vehicle for information and
guidance on the use of biologics including biosimilars. A large
majority of surveyed physicians prefer a modiﬁed label for bio-
similars which provides more information than the current label, in
terms of stating that the product is a biosimilar, as well as providing
further information on which clinical data were generated with
which product (the reference product or the biosimilar). Whether
the inclusion of such additional information may inﬂuence physi-
cians' treatment and care decisions on biosimilars needs to be
explored.
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